Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy

HOLON, Israel, Nov. 13, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that a patent for COM902, the Company's TIGIT therapeutic antibody candidate, has been issued by the United States Patent and Trademark Office (USPTO) under the USPTO's Cancer Moonshot Pilot Program providing early examination of patent applications pertaining to cancer immunotherapy.

The patent, U.S. Patent No. 10,124,061, relates to the method of using COM902 for activating T cells in cancer patients. Activating T cells results in stimulating the immune system, and therefore could be used for cancer immunotherapy treatment. The patent is expected to expire no earlier than August 2037 in the U.S. for the issued claims. This patent as well as other patents the Company is pursuing for COM902 are part of its global patent strategy covering its innovative immuno-oncology pipeline.

Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated, "Developing our own anti-TIGIT inhibitor is a key element in our combination strategy for COM701, our lead therapeutic program, currently in Phase 1 clinical trials, to allow for the combined inhibition of both PVRIG and TIGIT, the primary components of the DNAM axis. With U.S. patents granted for both COM701 and COM902, and with the only anti-PVRIG drug candidate currently available for clinical testing, we have a first-mover advantage in developing cancer treatments targeting this foundational axis for cancer immunotherapy."

"We selected COM902 as our therapeutic anti-TIGIT candidate due to its demonstrated synergistic activity with COM701 and because our data suggest that it is a potentially best-in-class TIGIT inhibitor, as it exhibits a higher binding affinity to TIGIT than other current clinical anti-TIGIT antibodies, while demonstrating superior preclinical potency," added Dr. Cohen-Dayag.

About COM902
COM902, a fully human antibody targeting TIGIT, was developed for combination use with COM701. Preclinical data support that inhibiting TIGIT alone, or in combination only with PD-1 blockade, will not generate a sufficient anti-tumor immune response in broad patient subpopulations. Rather, the data demonstrate that combined inhibition of both PVRIG and TIGIT, the two coinhibitory arms of the DNAM axis, is synergistic for T cell activation, tumor growth inhibition and anti-tumor activity in various model systems, and therefore may result in an enhanced clinical anti-tumor immune response.

The company expects to initiate Phase 1 clinical trials for COM902 in 2019.

About Compugen
Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel with R&D facilities in both Israel and South San Francisco, CA. Compugen's ordinary shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at

Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and describe opinions about possible future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors, including the ability to finance the Company, are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Tel: +972 (3) 765-8124

Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Tel: +1-212-213-0006

View original content:

SOURCE Compugen Ltd.